Literature DB >> 2247371

Immunocytochemical evaluation of neoplastic and non-neoplastic breast diseases with Mab A-80.

G K Koukoulis1, S S Shin, V E Gould, W Jao, G T Gooch, G L Manderino, H G Rittenhouse, J T Tomita.   

Abstract

Five hundred breast tissue samples from 404 cases were immunostained with A-80, a murine IgM Mab that recognizes a mucinous glycoprotein associated with exocrine differentiation. Samples included 196 primary breast carcinomas, 30 breast carcinoma metastases, 118 fibrocystic disease (FCD), and a further group of 84 samples of FCD from cases known to have breast carcinoma. These samples represented a broad spectrum of common and rare variants of carcinoma and FCD. Samples of fibroadenomas, lactating adenomas, cystosarcoma phylloides, gynecomastia, and normal breasts were similarly studied. The vast majority of carcinomas, 203/212 (95.7%) were immunoreactive; staining varied in extent and intensity, and was virtually unrelated to histologic type and to the presence or absence of recognizable glands. In samples including in-situ and infiltrating ductal or lobular carcinoma, reactivity was frequently stronger in the infiltrating components. No significant difference in reactivity between primary and metastatic carcinomas was noted. Of the group of 118 FCD, 27 were negative whereas 91 showed focal and weak staining. Seventy-two/84 FCD with associated carcinoma were immunostained; in 13 of those 72, staining was strong and extensive. Fibroadenomas, lactating adenomas, gynecomastia, and normal "resting" and lactating breast samples stained focally or not at all. Our findings indicate that Mab A-80 is an excellent immunohistochemical marker for the overwhelming majority of breast carcinomas whereas it marks weakly or not at all the majority of benign neoplasms and normal breast. Moreover, Mab A-80 recognizes a subset of FCD that includes proliferative variants associated with an increased incidence of carcinoma, and FCD in association with carcinoma. Questions regarding rare breast carcinomas that do not react with Mab A-80 remain unclear; yet, we believe that Mab A-80 is a highly promising marker of malignant and dysplastic breast epithelium.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2247371     DOI: 10.1016/s0344-0338(11)80461-9

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  Epithelial Proliferative Lesions and Carcinomas in Fibroadenomas of the Breast.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules.

Authors:  G K Koukoulis; I Virtanen; M Korhonen; L Laitinen; V Quaranta; V E Gould
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

3.  Increased numbers of cytokeratin-positive interstitial reticulum cells (CIRC) in reactive, inflammatory and neoplastic lymphadenopathies: hyperplasia or induced expression?

Authors:  V E Gould; K J Bloom; W W Franke; W H Warren; R Moll
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Immunohistochemical expression of the mucin-type glycoprotein A-80 and prognosis in human breast cancer.

Authors:  E T Eriksson; H Schimmelpenning; L E Rutqvist; H Johansson; G U Auer
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.